Amendments to the Drawings

The attached sheets of drawing includes changes to Fig. 1A, 1B, 2, 3, 4A, 4B, 4C, 4D, 5A, 5B, 5C, 6A, 6B, 7A, 7B, 7C, 8 and 9. These sheets replace the original sheets of drawings, i.e., Fig. 1A, 1B, 2, 3, 4a, 4b, 4c, 4d, 5a, 5b, 5c, 6A, 6B, 7A, 7b, 7C, 8 and 9.

In amended Figs. 1A, 1B, 2, 3, 4A, 4B, 4C, 4D, 5A, 5B, 5C, 6A, 6B, 7A, 7B, 7C, 8, the title, subtitle and/or reference to a general figure number were deleted. In amended Fig. 9, the draft schematic was formalized.

Attachment:


Replacement Sheets-Drawings

Annotated sheets showing changes-Drawings


Prelim. Amdt dated November 21, 2003 ANNOTATED SHEETS SHOWING CHANGES-DRAWINGS

Delivery of Rho-antagonist tissue adhesive formulation.

1A. Application of tissue adhesive + Rho antagonist to the injured spinal cord with a




Lesion of Corticospinal tract



Corticospinal tract lesion (untreated adult mice)


Axon retraction


Lesion



BEST AVAILABLE COPY

Figure 4a









Figure 4c



Figure 4d



BEST AVAILABLE COPY

Figure 5. Effect of C3/fibrin treatment on injured corticospinal tract

Figure 5a

Lesion

Regrowing fibres

Regrowing fibres

Figure 5b





Figure 5c



BEST AVAILABLE COPY

Figure 6: C3, brin-glue-treated s inal cord

Figure 6A





Figure 6B



BEST AVAILABLE COPY

Figure 7: Early Functional recovery

Figure 7A





Figure 7b



Delivery of C3



BBB tests show recovery after C3-treatment

Lecemeticn studies group

